BioLife Solutions, Inc.
BLFS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.83 | 0.20 | -0.00 | 0.36 |
| FCF Yield | 0.44% | -2.66% | -2.44% | -0.92% |
| EV / EBITDA | 738.05 | -15.87 | -6.42 | -83.59 |
| Quality | ||||
| ROIC | -1.87% | -18.66% | 0.12% | -2.10% |
| Gross Margin | 65.25% | 32.63% | 70.60% | 31.68% |
| Cash Conversion Ratio | -0.42 | 0.19 | 0.06 | 0.63 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.56% | 6.34% | 16.60% | 63.28% |
| Free Cash Flow Growth | 127.57% | -0.03% | -42.76% | -802.50% |
| Safety | ||||
| Net Debt / EBITDA | -42.57 | -0.16 | -0.20 | 2.58 |
| Interest Coverage | -9.92 | -39.09 | -8.62 | -72.49 |
| Efficiency | ||||
| Inventory Turnover | 0.99 | 2.22 | 3.09 | 2.87 |
| Cash Conversion Cycle | 365.55 | 185.62 | 228.54 | 131.20 |